Overview

• The attorneys general of New York, California, Massachusetts and New Jersey asked the FDA to eliminate REMS requirements for prescriber certification, pharmacy accreditation and patient attestation
• Health and Human Services Secretary Robert F. Kennedy Jr. directed FDA Commissioner Marty Makary to review mifepristone after a report from the Ethics and Public Policy Center alleged high rates of serious adverse events
• Reproductive health researchers have denounced the unreviewed report as junk science that overstates the risks of mifepristone
• FDA records show that fewer than 0.5% of users experience serious adverse reactions over 25 years and that the agency eased access by extending use to 10 weeks in 2016 and allowing telehealth prescriptions in 2021
• Seventeen other Democratic-led states and Washington, D.C. are pursuing a separate lawsuit in Spokane federal court to further loosen restrictions on the abortion pill